Menu Search
Equities

Exicure Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
2H0:FRA

Exicure Inc

Actions
  • Price (EUR)3.36
  • Today's Change-0.06 / -1.75%
  • Shares traded108.00
  • 1 Year change--
  • Beta4.1127
Data delayed at least 15 minutes, as of Feb 11 2026 07:05 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Exicure, Inc. is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The Company, through GPCR Therapeutics USA Inc. (GPCR USA), is focused on developing and commercializing an intellectual property and patents related to G-Protein Coupled Receptors. GPCR USA is conducting a Phase II clinical trial for a blood cancer treatment involving GPC-100 (Burixafor). The Company is also exploring strategic alternatives to maximize stockholder value.

  • Revenue in USD (TTM)0.00
  • Net income in USD-9.23m
  • Incorporated2017
  • Employees8.00
  • Location
    Exicure Inc2430 N. HALSTED ST.CHICAGO 60614United StatesUSA
  • Phone+1 (847) 673-1707
  • Fax+1 (847) 556-6411
  • Websitehttps://www.exicuretx.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.